VIP Reconstitution Calculator

No. VIP itself is an endogenous neuropeptide with broad physiologic actions, but the corpus here does not show an FDA-approved branded VIP drug for common outpatient use; available literature is mostly mechanistic, animal, formulation, and early human clinical work rather than registration trials (human clinical/animal/mechanistic). Most real-world use is investigational or compounded through specialty channels (practitioner consensus).

Research interest centers on anti-inflammatory, epithelial secretory, vasodilatory, neuroimmune, and circadian effects (mechanistic/review). In animal models, VIP reduced endotoxemia-associated TNF-α and IL-6, improved experimental colitis when delivered in nanomedicine form, promoted intestinal ILC3 recruitment and IL-22-dependent host defense, and slowed form-deprivation myopia after intravitreal administration. Human use most often discussed in practice is for inflammatory or mold-related syndromes, pulmonary/airway issues, or investigational neurologic applications (community protocol).

There is no strong head-to-head human dosing literature in this corpus comparing subcutaneous, intranasal, or inhaled routes for routine outpatient indications (human evidence gap). VIP is rapidly degraded in vivo and free peptide delivery can produce dose-limiting systemic effects such as hypotension, which is why formulation and route matter substantially. Practically, subcutaneous use is favored when reproducible systemic exposure is desired, while intranasal use is favored by some clinicians for convenience and CNS-targeting rationale (practitioner consensus); inhaled VIP has also been explored historically for pulmonary disease but remains niche (practitioner consensus).

Published human dosing details are sparse in this corpus; a migraine study confirms long-lasting infusion has been tested in humans, but this corpus does not provide a practical outpatient dose schedule. Common practitioner protocols for compounded VIP are intranasal 25-100 mcg once to four times daily or subcutaneous 50-200 mcg 1-2 times daily, usually started low because VIP is vasoactive (community protocol). Dose escalation is usually based on flushing, lightheadedness, bowel urgency, headache, and symptom response (practitioner consensus).

There is no well-defined chronic maintenance duration established by large human trials in this corpus (human evidence gap). Because VIP signaling affects ion secretion, motility, immune tone, and vascular tone, clinicians usually use finite trials of 4-12 weeks, then reassess symptoms, tolerability, and whether the underlying trigger is being addressed (practitioner consensus). Long-term daily use without monitoring is less evidence-based than short supervised courses (practitioner consensus).

The main practical issues are vasodilation-related symptoms and secretory GI effects. VIP lowers arterial pressure and has potent epithelial/intestinal secretory actions (mechanistic/review), and free peptide administration has been associated with hypotension severe enough to limit dosing, which improved with nanomedicine delivery in preclinical work. In practice, expected adverse effects are flushing, dizziness, tachycardia, headache, nasal irritation if sprayed intranasally, loose stools, abdominal cramping, and occasionally worsened migraine-like symptoms from vasodilation (mechanistic/human clinical/community protocol).

Use caution in people with low baseline blood pressure, orthostatic intolerance, active diarrhea, severe uncontrolled asthma/allergy flares, or significant migraine sensitivity because VIP is vasoactive and immunomodulatory (mechanistic/review). Pregnancy and breastfeeding data are not established in this corpus, so routine use is not evidence-supported in those settings (human evidence gap). People on multiple antihypertensives, PDE5 inhibitors, nitrates, or other vasodilators should be extra cautious because additive hypotension is plausible from mechanism (mechanistic).

VIP and PACAP overlap strongly in receptor biology and anti-inflammatory signaling, and both protected mice from lethal endotoxemia by suppressing TNF-α and IL-6. VIP is especially emphasized in gut epithelial, motility, ion transport, and mucosal immune homeostasis, whereas PACAP often gets more attention in neuroprotection and overlapping neuroimmune roles (mechanistic/review). In practice, VIP is more commonly sought when the target is gut, airway, or broad neuroimmune regulation; PACAP is less commonly used clinically and more often discussed mechanistically (practitioner consensus).

VIP biology is context-dependent. Its receptors are tissue-specific, especially VPAC1 in the intestine, and VIP can exert different immune effects depending on receptor distribution and microenvironment. Chemically, VIP can also undergo tyrosine nitration in inflammatory conditions, which may attenuate its anti-inflammatory effect. Practically, poor response can reflect receptor context, inflammatory redox stress, underdosing, peptide instability, or simply the wrong indication (mechanistic/practitioner consensus).

Usually yes for compounded peptide products, because peptides are generally handled cold to preserve stability; the corpus documents rapid in vivo degradation as a key delivery problem, supporting careful handling even though explicit storage specifications are not given here. Standard practice is refrigerated storage at 2-8°C, minimizing heat/light exposure, and transporting with an insulated cold pack; brief room-temperature exposure during travel is commonly tolerated depending on the pharmacy formulation (community protocol). For flights, keep labeled vials or spray bottles in original packaging and carry them on rather than checking them (practitioner consensus).